IL141241A0 - Method for administering insulinotropic peptides - Google Patents

Method for administering insulinotropic peptides

Info

Publication number: IL141241A0
Authority: IL; Israel
Prior art keywords: administering; insulinotropic peptides; insulinotropic; peptides; administering insulinotropic
Prior art date: 1998-08-28

Application number

IL14124199A

Other languages

English (en)

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-28

Filing date

1999-08-24

Publication date

2002-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL141241(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-08-24 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2002-03-10 Publication of IL141241A0 publication Critical patent/IL141241A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

IL14124199A 1998-08-28 1999-08-24 Method for administering insulinotropic peptides IL141241A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9827398P	1998-08-28	1998-08-28
US10001298P	1998-09-11	1998-09-11
PCT/US1999/019348 WO2000012116A1 (en)	1998-08-28	1999-08-24	Method for administering insulinotropic peptides

Publications (1)

Publication Number	Publication Date
IL141241A0 true IL141241A0 (en)	2002-03-10

Family

ID=26794577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14124199A IL141241A0 (en)	1998-08-28	1999-08-24	Method for administering insulinotropic peptides

Country Status (21)

Country	Link
EP (1)	EP0997151B1 (es)
JP (1)	JP2002523466A (es)
KR (1)	KR20010073033A (es)
CN (1)	CN1314818A (es)
AR (1)	AR022368A1 (es)
AT (1)	ATE347902T1 (es)
AU (1)	AU764371B2 (es)
BR (1)	BR9913284A (es)
CA (1)	CA2341454A1 (es)
CO (1)	CO5090908A1 (es)
CZ (1)	CZ2001690A3 (es)
DE (1)	DE69934380D1 (es)
EA (1)	EA200100289A1 (es)
HR (1)	HRP20010141A2 (es)
HU (1)	HUP0103369A3 (es)
IL (1)	IL141241A0 (es)
NO (1)	NO20010982L (es)
PE (1)	PE20001031A1 (es)
PL (1)	PL346317A1 (es)
TR (1)	TR200100600T2 (es)
WO (1)	WO2000012116A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP1250126A2 (en) *	2000-01-11	2002-10-23	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) *	2000-01-25	2003-04-01	Aeropharm Technology Incorporated	Medical aerosol formulation
WO2001093837A2 (en) *	2000-06-08	2001-12-13	Eli Lilly And Company	Protein powder for pulmonary delivery
NZ523693A (en) *	2000-07-10	2004-08-27	Chiron Corp	Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2002308706A1 (en) *	2001-06-01	2002-12-16	Eli Lilly And Company	Glp-1 formulations with protracted time action
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
CN1630709A (zh)	2001-10-18	2005-06-22	百时美施贵宝公司	人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
PT1494732E (pt)	2002-03-20	2008-03-20	Mannkind Corp	Aparelho de inalação
AU2003257156B2 (en) *	2002-08-01	2007-08-30	Mannkind Corporation	Cell transport compositions and uses thereof
US8921311B2 (en)	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
MXPA06006745A (es)	2003-12-18	2006-08-18	Novo Nordisk As	Compuestos glp-1 novedosos.
BRPI0514263B8 (pt)	2004-08-20	2021-05-25	Mannkind Corp	método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
CA2578175C (en)	2004-08-23	2014-10-14	Mannkind Corporation	Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
KR100704447B1 (ko) *	2005-05-16	2007-04-09	정용현	3단계로 코팅되는 김치 유산균의 코팅방법 및 그로부터 제조된 코팅된 김치유산균 및 코팅된 김치 유산균이 함유된 조성물
EP1937219B1 (en)	2005-09-14	2015-11-11	MannKind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
EP1965823B1 (en) *	2005-11-04	2016-05-18	Glaxosmithkline LLC	Methods for administering hypoglycemic agents
US8293869B2 (en)	2005-12-16	2012-10-23	Nektar Therapeutics	Polymer conjugates of GLP-1
IN2015DN00888A (es)	2006-02-22	2015-07-10	Mannkind Corp
TWI430806B (zh) *	2006-09-13	2014-03-21	Smithkline Beecham Corp	用於投與長效降血糖藥劑之方法
WO2008132224A2 (en)	2007-04-30	2008-11-06	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2009019027A (ja)	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2011163272A1 (en)	2010-06-21	2011-12-29	Mannkind Corporation	Dry powder drug delivery system and methods
BRPI0818872A2 (pt) *	2007-10-24	2015-05-05	Mannkind Corp	Método para prevenir efeitos adversos por glp-1
PL2293833T3 (pl)	2008-06-13	2016-08-31	Mannkind Corp	Inhalator proszkowy i układ do dostarczania leku
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
DK2609954T3 (da)	2008-06-20	2022-02-14	Mannkind Corp	Interaktivt apparat til realtidsafbildning af inhalationspræstationer
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2853268A1 (en)	2009-01-08	2015-04-01	Mannkind Corporation	Treatment of hyperglycemia with GLP-1
PL2405963T3 (pl)	2009-03-11	2014-04-30	Mannkind Corp	Urządzenie, układ i sposób pomiaru oporu inhalatora
KR102584844B1 (ko)	2009-06-12	2023-10-04	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
JP5784622B2 (ja)	2009-11-03	2015-09-24	マンカインドコーポレ−ション	吸入活動をシミュレートするための装置及び方法
SG10201606220QA (en)	2011-04-01	2016-09-29	Mannkind Corp	Blister package for pharmaceutical cartridges
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
US9233159B2 (en)	2011-10-24	2016-01-12	Mannkind Corporation	Methods and compositions for treating pain
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
BR112015023168B1 (pt)	2013-03-15	2021-08-10	Mannkind Corporation	Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
CA2918369C (en)	2013-07-18	2021-06-29	Mannkind Corporation	Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
WO2018155254A1 (ja)	2017-02-21	2018-08-30	Ｊｆｅスチール株式会社	高炭素熱延鋼板およびその製造方法
GB201917723D0 (en)	2019-12-04	2020-01-15	Nv Rose Llc	Stable liquid formulations of glucagon-like peptide 1 or analogues thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
HU225496B1 (en) *	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
RU2214419C2 (ru) *	1996-08-30	2003-10-20	Ново Нордиск А/С	Glp-1 производные
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6153211A (en) *	1997-07-18	2000-11-28	Infimed, Inc.	Biodegradable macromers for the controlled release of biologically active substances

1999
- 1999-08-24 JP JP2000567230A patent/JP2002523466A/ja not_active Withdrawn
- 1999-08-24 PL PL99346317A patent/PL346317A1/xx not_active Application Discontinuation
- 1999-08-24 WO PCT/US1999/019348 patent/WO2000012116A1/en not_active Application Discontinuation
- 1999-08-24 CZ CZ2001690A patent/CZ2001690A3/cs unknown
- 1999-08-24 EA EA200100289A patent/EA200100289A1/ru unknown
- 1999-08-24 KR KR1020017002518A patent/KR20010073033A/ko not_active Application Discontinuation
- 1999-08-24 BR BR9913284-2A patent/BR9913284A/pt not_active IP Right Cessation
- 1999-08-24 AR ARP990104231A patent/AR022368A1/es unknown
- 1999-08-24 CO CO99053457A patent/CO5090908A1/es unknown
- 1999-08-24 AU AU55841/99A patent/AU764371B2/en not_active Ceased
- 1999-08-24 CN CN99810174A patent/CN1314818A/zh active Pending
- 1999-08-24 CA CA002341454A patent/CA2341454A1/en not_active Abandoned
- 1999-08-24 IL IL14124199A patent/IL141241A0/xx unknown
- 1999-08-24 TR TR2001/00600T patent/TR200100600T2/xx unknown
- 1999-08-24 HU HU0103369A patent/HUP0103369A3/hu unknown
- 1999-08-25 DE DE69934380T patent/DE69934380D1/de not_active Expired - Lifetime
- 1999-08-25 PE PE1999000857A patent/PE20001031A1/es not_active Application Discontinuation
- 1999-08-25 AT AT99306733T patent/ATE347902T1/de not_active IP Right Cessation
- 1999-08-25 EP EP99306733A patent/EP0997151B1/en not_active Revoked
2001
- 2001-02-27 HR HR20010141A patent/HRP20010141A2/hr not_active Application Discontinuation
- 2001-02-27 NO NO20010982A patent/NO20010982L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0103369A2 (hu)	2002-02-28
PL346317A1 (en)	2002-01-28
CN1314818A (zh)	2001-09-26
JP2002523466A (ja)	2002-07-30
WO2000012116A1 (en)	2000-03-09
EP0997151B1 (en)	2006-12-13
CZ2001690A3 (cs)	2002-04-17
EP0997151A2 (en)	2000-05-03
AU764371B2 (en)	2003-08-14
CO5090908A1 (es)	2001-10-30
AU5584199A (en)	2000-03-21
ATE347902T1 (de)	2007-01-15
NO20010982D0 (no)	2001-02-27
DE69934380D1 (de)	2007-01-25
EA200100289A1 (ru)	2001-10-22
HUP0103369A3 (en)	2002-03-28
PE20001031A1 (es)	2000-10-12
NO20010982L (no)	2001-04-27
AR022368A1 (es)	2002-09-04
TR200100600T2 (tr)	2001-07-23
EP0997151A3 (en)	2000-09-20
BR9913284A (pt)	2001-05-15
CA2341454A1 (en)	2000-03-09
HRP20010141A2 (en)	2002-02-28
KR20010073033A (ko)	2001-07-31

Publication	Publication Date	Title
PL346317A1 (en)	2002-01-28	Method for administering insulinotropic peptides
IL137105A0 (en)	2001-06-14	Method for administering aspb28-human insulin
HK1036997A1 (en)	2002-01-25	Peptides
ZA989744B (en)	2000-04-26	Method for administering acylated insulin.
GB0128994D0 (en)	2002-01-23	Peptides
GB2352623B (en)	2004-01-07	Seating apparatus
IL146743A0 (en)	2002-07-25	Screening method for peptides
GB9825854D0 (en)	1999-01-20	Peptide
GB9713283D0 (en)	1997-08-27	Method for preparing aminoalkoxysiloxanes
GB9930298D0 (en)	2000-02-09	Imaging method
IL136878A0 (en)	2001-06-14	Method for inhaling powdery substances
GB9812675D0 (en)	1998-08-12	Peptides
EP1147130A4 (en)	2004-09-29	ALPHA-conotoxin PEPTIDE
GB9823835D0 (en)	1998-12-23	Component for vaccine
GB9904695D0 (en)	1999-04-21	Peptide
HUP0003496A3 (en)	2002-12-28	Method for preparing oxazaphosphorin-2-amines
GB0120713D0 (en)	2001-10-17	Peptides
GB9908920D0 (en)	1999-06-16	Peptide
GB9807890D0 (en)	1998-06-10	Peptides
HK1045173A1 (zh)	2002-11-15	多肽
GB9918680D0 (en)	1999-10-13	Polypeptide
GB9810681D0 (en)	1998-07-15	Hormone
AU140500S (en)	2000-04-20	Seating apparatus
HU9902898D0 (en)	1999-10-28	Method for influancing thermosensibility
GB9818368D0 (en)	1998-10-21	Vitronectin-derived peptides